Indrayani Biotech Limited's Board of Directors has formally accepted the resignation of its Whole-time Director following the scheduled Board meeting. The Company received the resignation letter on March 19, 2026, and has now completed the formal acceptance process as per regulatory requirements.

Director Resignation and Board Acceptance

The Board of Directors, at its meeting held on March 24, 2026, formally accepted the resignation of Mr. Singarababu Indirakumar from his position as Whole-time Director. The resignation details and timeline are as follows:

Mr. Singarababu Indirakumar has been relieved from his duties effective from the close of business hours on March 24, 2026. The director had originally tendered his resignation on March 16, 2026, which the Company received on March 19, 2026.

Board Meeting Proceedings

The Board meeting was conducted as scheduled on March 24, 2026, at 11:00 AM at the Company's registered office. During the meeting, the Board deliberated on the resignation letter and formally accepted the resignation as submitted. The Company Secretary, Ramya Ravi, communicated the Board's decision to the BSE on the same day.

Prior to the Board meeting, Mr. Indirakumar had sent an email on March 20, 2026, clarifying that the Board meeting notice was not applicable to him as he had already resigned on March 16, 2026, with intimation to the Registrar of Companies and other relevant authorities.

Regulatory Compliance and Disclosure

Indrayani Biotech has maintained full regulatory compliance throughout this transition process. The Company has fulfilled its obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by providing timely disclosures to the BSE.

The Company has provided comprehensive details in Annexure-I, including the director's name, DIN, designation, reason for change, and effective dates as required under the relevant SEBI circulars and regulations. This ensures complete transparency with stakeholders and maintains the Company's commitment to regulatory compliance during leadership transitions.

Indrayani Biotech Limited announced its unaudited financial results for the quarter ended December 31, 2025, along with significant leadership changes and strategic financial decisions. The Board of Directors, meeting on February 26, 2026, approved the quarterly results and made several important corporate announcements.

Financial Performance Overview

The company's standalone financial performance for Q3FY26 showed mixed results compared to the previous year. Revenue from operations declined to ₹520.10 lakhs from ₹818.82 lakhs in the corresponding quarter of the previous year. Despite the revenue decline, the company maintained profitability with a net profit of ₹8.02 lakhs compared to ₹10.61 lakhs in Q3FY25.

Consolidated Results Show Stronger Performance

On a consolidated basis, Indrayani Biotech demonstrated significantly stronger performance. Consolidated revenue from operations reached ₹3,501.48 lakhs for Q3FY26, substantially higher than ₹1,731.82 lakhs in the corresponding quarter of the previous year. The consolidated net profit stood at ₹11.55 lakhs compared to ₹35.15 lakhs in Q3FY25.

Leadership Transition in Finance Function

The Board approved significant changes in the company's finance leadership. Mr. Dhinakaran Rajagopal resigned from his position as Chief Financial Officer effective February 26, 2026, citing personal reasons. The company simultaneously appointed Mr. Kunisetty Venkateswara Rao as the new Chief Financial Officer, effective February 27, 2026.

Mr. Kunisetty Venkateswara Rao brings extensive experience to the role:

• Qualified Chartered Accountant and Bachelor in Commerce
• Fellow Member of the Institute of Chartered Accountants of India (ICAI)
• Over 30 years of experience in financial management, corporate finance, and strategic planning
• Expertise in taxation, audit, compliance, and regulatory matters

Strategic Financial Initiatives

The Board approved several strategic financial decisions to support the company's growth objectives. The company secured approval for credit facilities worth ₹5 crores from Indus Finance Limited, which will provide additional financial flexibility for operations and expansion.

Regarding the Rights Issue, the company received in-principle approval from BSE Limited on September 19, 2025, for its proposed partly paid-up Rights Issue. The Board resolved to expedite this process and complete the Rights Issue within prescribed timelines in compliance with SEBI (ICDR) Regulations, 2018.

Compliance and Regulatory Matters

The Board addressed previous compliance issues with BSE Limited regarding delays in regulatory filings. The company faced fines for late submission of financial results for September 2025 under Regulation 33 (₹1,47,500) and delays in board meeting intimations under Regulation 29 (₹11,800). Both fines have been paid and the matters now stand resolved.

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the standalone performance showed revenue from operations of ₹1,781.80 lakhs with net profit of ₹67.63 lakhs. On a consolidated basis, the company achieved revenue of ₹10,006.70 lakhs with net profit of ₹118.41 lakhs, demonstrating the strength of the group's diversified operations across its subsidiary companies.